Senti Biosciences Holdings, Inc. Cash Flow Statement
SNTI|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Senti Biosciences Holdings, Inc. used $41M in operating cash flow and negative free cash flow of $41M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| Depreciation & Amortization | $3.8M | $3.6M | $1.4M | $769.0K |
| Operating Cash Flow | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Capital Expenditures | $26.0K | $12.0M | $41.4M | $5.5M |
| Free Cash Flow | -$41.4M | -$64.4M | -$76.3M | -$40.2M |
| FCF Margin | - | -2515.9% | -1779.5% | -1455.2% |